[
  {
    "sentence": "The secondary aims were to study the vaccination effect in certain subgroups of patients with hematological neoplasms as well as the effect in patients receiving specific hematological treatments.Methods\nSetting\nThe base population for this study was the population of Clalit Health Services (CHS), the largest health care organization in Israel, which insures 4.7 million people (52% of the population).Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Analyses were performed with the use of R software, version 4.0.Ethics\nThis study was approved by the CHS Institutional Review Board.Results\nOverall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Note that in all outcomes, the patients with hematological neoplasms fared worse.Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.Focusing on particular hematological neoplasms resulted in smaller groups with small numbers of events, but the trend was mostly similar.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The secondary aims were to study the vaccination effect in certain subgroups of patients with hematological neoplasms as well as the effect in patients receiving specific hematological treatments.Methods\nSetting\nThe base population for this study was the population of Clalit Health Services (CHS), the largest health care organization in Israel, which insures 4.7 million people (52% of the population).Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Analyses were performed with the use of R software, version 4.0.Ethics\nThis study was approved by the CHS Institutional Review Board.Results\nOverall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Note that in all outcomes, the patients with hematological neoplasms fared worse.Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.Focusing on particular hematological neoplasms resulted in smaller groups with small numbers of events, but the trend was mostly similar.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The secondary aims were to study the vaccination effect in certain subgroups of patients with hematological neoplasms as well as the effect in patients receiving specific hematological treatments.Methods\nSetting\nThe base population for this study was the population of Clalit Health Services (CHS), the largest health care organization in Israel, which insures 4.7 million people (52% of the population).Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Analyses were performed with the use of R software, version 4.0.Ethics\nThis study was approved by the CHS Institutional Review Board.Results\nOverall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Note that in all outcomes, the patients with hematological neoplasms fared worse.Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.Focusing on particular hematological neoplasms resulted in smaller groups with small numbers of events, but the trend was mostly similar.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The secondary aims were to study the vaccination effect in certain subgroups of patients with hematological neoplasms as well as the effect in patients receiving specific hematological treatments.Methods\nSetting\nThe base population for this study was the population of Clalit Health Services (CHS), the largest health care organization in Israel, which insures 4.7 million people (52% of the population).Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Analyses were performed with the use of R software, version 4.0.Ethics\nThis study was approved by the CHS Institutional Review Board.Results\nOverall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Note that in all outcomes, the patients with hematological neoplasms fared worse.Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.Focusing on particular hematological neoplasms resulted in smaller groups with small numbers of events, but the trend was mostly similar.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The secondary aims were to study the vaccination effect in certain subgroups of patients with hematological neoplasms as well as the effect in patients receiving specific hematological treatments.Methods\nSetting\nThe base population for this study was the population of Clalit Health Services (CHS), the largest health care organization in Israel, which insures 4.7 million people (52% of the population).Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Analyses were performed with the use of R software, version 4.0.Ethics\nThis study was approved by the CHS Institutional Review Board.Results\nOverall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Note that in all outcomes, the patients with hematological neoplasms fared worse.Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.Focusing on particular hematological neoplasms resulted in smaller groups with small numbers of events, but the trend was mostly similar.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The secondary aims were to study the vaccination effect in certain subgroups of patients with hematological neoplasms as well as the effect in patients receiving specific hematological treatments.Methods\nSetting\nThe base population for this study was the population of Clalit Health Services (CHS), the largest health care organization in Israel, which insures 4.7 million people (52% of the population).Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Analyses were performed with the use of R software, version 4.0.Ethics\nThis study was approved by the CHS Institutional Review Board.Results\nOverall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Note that in all outcomes, the patients with hematological neoplasms fared worse.Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.Focusing on particular hematological neoplasms resulted in smaller groups with small numbers of events, but the trend was mostly similar.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The secondary aims were to study the vaccination effect in certain subgroups of patients with hematological neoplasms as well as the effect in patients receiving specific hematological treatments.Methods\nSetting\nThe base population for this study was the population of Clalit Health Services (CHS), the largest health care organization in Israel, which insures 4.7 million people (52% of the population).Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Analyses were performed with the use of R software, version 4.0.Ethics\nThis study was approved by the CHS Institutional Review Board.Results\nOverall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Note that in all outcomes, the patients with hematological neoplasms fared worse.Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.Focusing on particular hematological neoplasms resulted in smaller groups with small numbers of events, but the trend was mostly similar.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The secondary aims were to study the vaccination effect in certain subgroups of patients with hematological neoplasms as well as the effect in patients receiving specific hematological treatments.Methods\nSetting\nThe base population for this study was the population of Clalit Health Services (CHS), the largest health care organization in Israel, which insures 4.7 million people (52% of the population).Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Analyses were performed with the use of R software, version 4.0.Ethics\nThis study was approved by the CHS Institutional Review Board.Results\nOverall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Note that in all outcomes, the patients with hematological neoplasms fared worse.Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.Focusing on particular hematological neoplasms resulted in smaller groups with small numbers of events, but the trend was mostly similar.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Methods\nSetting\nThe base population for this study was the population of Clalit Health Services (CHS), the largest health care organization in Israel, which insures 4.7 million people (52% of the population).Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patient population\nOf 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Patients were eligible to be included in the exposed group of patients with hematological neoplasms if they fulfilled 1 of the following criteria: (1) documented diagnosis of a hematological neoplasm (according to International Classification of Diseases, 9th edition, codes or Clalit diagnostic criteria) during the 6 months preceding data extraction, with or without chemotherapy or biologic therapy; (2) documented diagnosis of hematological neoplasm and a referral to an inpatient or outpatient clinic and/or daycare for administration of hematological treatment during the 6 months preceding data extraction; or (3) active chemotherapy and/or biologic therapy that is used exclusively for hematologic patients. (See supplemental Materials, available on the Blood Web site, for a list of diagnoses of hematological neoplasms and treatments.)\nFigure 1.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Of 1 583 251 CHS members who were vaccinated before 28 February 2021, 37 899 were eligible for the study and 32 516 were matched to unvaccinated controls (Figure 1).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Results\nOverall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Note that in all outcomes, the patients with hematological neoplasms fared worse.Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.Focusing on particular hematological neoplasms resulted in smaller groups with small numbers of events, but the trend was mostly similar.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Overall, 32 156 individuals with a hematological neoplasm met the inclusion criteria and served as the exposed group in this study (Figure 1), which was matched to vaccinated controls without hematological neoplasm.",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Vaccinated patients with hematological neoplasms were found to suffer from COVID-19 more than vaccinated matched controls (Table 2; Figure 2).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Restriction of the analysis to patients with actively treated hematological neoplasms increased RR (Table 2; Figure 3).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Kaplan-Meier curves of the same outcomes demonstrated in Figure 2, with blue and red curves representing vaccinated patients and vaccinated controls, respectively.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The difference (RR) between the patient and control groups is even more prominent than that represented in Figure 2.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "",
        "figure_key": "figure_2"
      }
    ]
  }
]